|
ES2116269T3
(es)
|
1989-03-21 |
1998-07-16 |
Vical Inc |
Expresion de secuencias exogenas de polinucleotidos en un vertebrado.
|
|
US6867195B1
(en)
|
1989-03-21 |
2005-03-15 |
Vical Incorporated |
Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
|
|
FR2676072B1
(fr)
|
1991-05-03 |
1994-11-18 |
Transgene Sa |
Vecteur de delivrance d'arn.
|
|
EP0855184A1
(en)
|
1997-01-23 |
1998-07-29 |
Grayson B. Dr. Lipford |
Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
|
|
US6251665B1
(en)
|
1997-02-07 |
2001-06-26 |
Cem Cezayirli |
Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom
|
|
US6261281B1
(en)
|
1997-04-03 |
2001-07-17 |
Electrofect As |
Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
|
|
EP1021548A1
(en)
|
1997-10-07 |
2000-07-26 |
University Of Maryland Biotechnology Institute |
Method for introducing and expressing rna in animal cells
|
|
US6432925B1
(en)
|
1998-04-16 |
2002-08-13 |
John Wayne Cancer Institute |
RNA cancer vaccine and methods for its use
|
|
US8206749B1
(en)
|
1999-02-26 |
2012-06-26 |
Novartis Vaccines And Diagnostics, Inc. |
Microemulsions with adsorbed macromolecules and microparticles
|
|
US6514948B1
(en)
|
1999-07-02 |
2003-02-04 |
The Regents Of The University Of California |
Method for enhancing an immune response
|
|
ATE289630T1
(de)
|
1999-09-09 |
2005-03-15 |
Curevac Gmbh |
Transfer von mrnas unter verwendung von polykationischen verbindungen
|
|
AU7398200A
(en)
|
1999-09-17 |
2001-04-24 |
Aventis Pasteur Limited |
Chlamydia antigens and corresponding dna fragments and uses thereof
|
|
US7060291B1
(en)
|
1999-11-24 |
2006-06-13 |
Transave, Inc. |
Modular targeted liposomal delivery system
|
|
GB2367249B
(en)
*
|
2000-07-18 |
2004-06-23 |
Robert Patrick Hart |
Underwater breathing device
|
|
WO2002008435A1
(en)
|
2000-07-21 |
2002-01-31 |
Glaxo Group Limited |
Codon-optimized papilloma virus sequences
|
|
DE50211110D1
(de)
|
2001-04-21 |
2007-12-06 |
Curevac Gmbh |
INJEKTIONSGERÄT FÜR mRNA APPLIKATION
|
|
ATE490267T1
(de)
|
2001-06-05 |
2010-12-15 |
Curevac Gmbh |
Stabilisierte mrna mit erhöhtem g/c-gehalt, kodierend für ein virales antigen
|
|
DE10162480A1
(de)
|
2001-12-19 |
2003-08-07 |
Ingmar Hoerr |
Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
|
|
US8153141B2
(en)
|
2002-04-04 |
2012-04-10 |
Coley Pharmaceutical Gmbh |
Immunostimulatory G, U-containing oligoribonucleotides
|
|
DE10229872A1
(de)
|
2002-07-03 |
2004-01-29 |
Curevac Gmbh |
Immunstimulation durch chemisch modifizierte RNA
|
|
WO2004058166A2
(en)
|
2002-12-23 |
2004-07-15 |
Vical Incorporated |
Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
|
|
DE602004021260D1
(de)
|
2003-07-11 |
2009-07-09 |
Alphavax Inc |
Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
|
|
DE10347710B4
(de)
|
2003-10-14 |
2006-03-30 |
Johannes-Gutenberg-Universität Mainz |
Rekombinante Impfstoffe und deren Verwendung
|
|
DE102006007433A1
(de)
|
2006-02-17 |
2007-08-23 |
Curevac Gmbh |
Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure
|
|
AU2007280690C1
(en)
|
2006-07-31 |
2012-08-23 |
Curevac Gmbh |
Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant
|
|
CN101148661B
(zh)
*
|
2006-09-18 |
2013-01-02 |
中国医学科学院基础医学研究所 |
人乳头瘤病毒16型外壳蛋白病毒样颗粒及其制备方法和用途
|
|
DE102006051516A1
(de)
|
2006-10-31 |
2008-05-08 |
Curevac Gmbh |
(Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
|
|
DE102007001370A1
(de)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
|
BRPI0810951B8
(pt)
*
|
2007-05-29 |
2021-05-25 |
Beijing Wantai Biological Pharmacy Entpr Co Ltd |
proteína l1 do hpv6, polinucleotídeo, vetor, célula, partícula semelhante ao vírus (vlp) hpv6, método para produzir a proteína hpv6 l1 truncada, vacina para prevenção de condiloma acuminado ou de infecções por hpv, uso da proteína hpv6 l1 truncada, método para prevenção de condiloma acuminado ou infecções por hpv, método para obter uma vlp de uma proteína l1 do hpv6 e método para produzir uma vacina para a prevenção de condiloma acuminado ou de infecções por hpv
|
|
WO2009030254A1
(en)
|
2007-09-04 |
2009-03-12 |
Curevac Gmbh |
Complexes of rna and cationic peptides for transfection and for immunostimulation
|
|
EP2630966B1
(en)
|
2007-10-12 |
2017-04-19 |
Massachusetts Institute of Technology |
Vaccine nanotechnology
|
|
AU2009238175C1
(en)
|
2008-04-15 |
2023-11-30 |
Arbutus Biopharma Corporation |
Novel lipid formulations for nucleic acid delivery
|
|
JP2012501965A
(ja)
|
2008-06-16 |
2012-01-26 |
バインド バイオサイエンシズ インコーポレイテッド |
薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法
|
|
WO2010037408A1
(en)
*
|
2008-09-30 |
2010-04-08 |
Curevac Gmbh |
Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
|
|
CN104119242B
(zh)
|
2008-10-09 |
2017-07-07 |
泰米拉制药公司 |
改善的氨基脂质和递送核酸的方法
|
|
HUE037082T2
(hu)
|
2008-11-10 |
2018-08-28 |
Arbutus Biopharma Corp |
Új lipidek és készítmények terápiás hatóanyagok szállítására
|
|
US8734853B2
(en)
|
2008-11-17 |
2014-05-27 |
University Of North Texas Health Science Center At Fort Worth |
HDL particles for delivery of nucleic acids
|
|
WO2010088927A1
(en)
|
2009-02-09 |
2010-08-12 |
Curevac Gmbh |
Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds
|
|
US9764012B2
(en)
|
2009-04-01 |
2017-09-19 |
University Of Miami |
Vaccine compositions and methods of use thereof
|
|
US8569256B2
(en)
|
2009-07-01 |
2013-10-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
|
US20110300205A1
(en)
|
2009-07-06 |
2011-12-08 |
Novartis Ag |
Self replicating rna molecules and uses thereof
|
|
WO2011069529A1
(en)
|
2009-12-09 |
2011-06-16 |
Curevac Gmbh |
Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
|
|
EP2387999A1
(en)
|
2010-05-21 |
2011-11-23 |
CureVac GmbH |
Histidine-containing solution for transfection and/or injection of nucleic acids and uses thereof
|
|
HUE026646T2
(en)
|
2010-07-06 |
2016-07-28 |
Glaxosmithkline Biologicals Sa |
Preferred liposomes containing lipids of PKA value for delivery of RNA
|
|
RS63817B1
(sr)
|
2010-07-06 |
2023-01-31 |
Glaxosmithkline Biologicals Sa |
Čestice za isporuku slične virionu za molekule samoreplicirajuće rnk
|
|
EP2590625B1
(en)
|
2010-07-06 |
2017-09-20 |
GlaxoSmithKline Biologicals SA |
Cationic oil-in-water emulsions
|
|
PL2591114T3
(pl)
|
2010-07-06 |
2017-08-31 |
Glaxosmithkline Biologicals Sa |
Immunizacja dużych ssaków małymi dawkami rna
|
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
|
CA2801523C
(en)
|
2010-07-30 |
2021-08-03 |
Curevac Gmbh |
Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
|
|
WO2012019168A2
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
WO2012019630A1
(en)
|
2010-08-13 |
2012-02-16 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
|
|
RS63890B1
(sr)
|
2010-08-31 |
2023-02-28 |
Glaxosmithkline Biologicals Sa |
Mali lipozomi za isporuku rnk koja kodira imunogen
|
|
PT3970742T
(pt)
|
2010-08-31 |
2022-06-27 |
Glaxosmithkline Biologicals Sa |
Lipossomas peguilados para entrega de arn codificador de imunogénio
|
|
ES2727583T3
(es)
|
2010-08-31 |
2019-10-17 |
Glaxosmithkline Biologicals Sa |
Lípidos adecuados para la administración liposómica de ARN que codifica proteínas
|
|
RU2013120302A
(ru)
|
2010-10-01 |
2014-11-20 |
Модерна Терапьютикс, Инк. |
Сконструированные нуклеиновые кислоты и способы их применения
|
|
WO2012075040A2
(en)
|
2010-11-30 |
2012-06-07 |
Shire Human Genetic Therapies, Inc. |
mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
|
|
WO2012089225A1
(en)
|
2010-12-29 |
2012-07-05 |
Curevac Gmbh |
Combination of vaccination and inhibition of mhc class i restricted antigen presentation
|
|
WO2012099805A2
(en)
|
2011-01-19 |
2012-07-26 |
Ocean Nanotech, Llc |
Nanoparticle based immunological stimulation
|
|
WO2012116715A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in newborns and infants
|
|
WO2012113413A1
(en)
|
2011-02-21 |
2012-08-30 |
Curevac Gmbh |
Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
|
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
|
EP2691101A2
(en)
|
2011-03-31 |
2014-02-05 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
WO2012158736A1
(en)
|
2011-05-17 |
2012-11-22 |
modeRNA Therapeutics |
Engineered nucleic acids and methods of use thereof for non-human vertebrates
|
|
CN103857387B
(zh)
|
2011-06-02 |
2017-03-15 |
加利福尼亚大学董事会 |
膜包封的纳米颗粒及使用方法
|
|
US11058762B2
(en)
|
2011-07-06 |
2021-07-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions and uses thereof
|
|
CA2840965C
(en)
|
2011-07-06 |
2021-03-02 |
Novartis Ag |
Cationic oil-in-water emulsions
|
|
WO2013006838A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic combination compositions and uses thereof
|
|
US20140141070A1
(en)
*
|
2011-07-06 |
2014-05-22 |
Andrew Geall |
Liposomes having useful n:p ratio for delivery of rna molecules
|
|
CN103930547A
(zh)
|
2011-09-02 |
2014-07-16 |
诺华股份有限公司 |
用于治疗hsf1相关疾病的有机组合物
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP3384938A1
(en)
|
2011-09-12 |
2018-10-10 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
RU2648950C2
(ru)
*
|
2011-10-03 |
2018-04-02 |
Модерна Терапьютикс, Инк. |
Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
|
|
BR112014008694A2
(pt)
|
2011-10-11 |
2017-06-20 |
Novartis Ag |
moléculas de ácido nucleico policistrônico recombinante
|
|
JP2014532071A
(ja)
|
2011-10-14 |
2014-12-04 |
エスティーシー． ユーエヌエムＳｔｃ．Ｕｎｍ |
カーゴの経皮送達を含む標的送達用の多孔性ナノ粒子に担持された脂質二重層（プロトセル）及びその方法
|
|
JP6294229B2
(ja)
|
2011-10-18 |
2018-03-14 |
ダイセルナ ファーマシューティカルズ， インコーポレイテッドＤｉｃｅｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
アミン陽イオン性脂質およびその使用
|
|
US20140378538A1
(en)
|
2011-12-14 |
2014-12-25 |
Moderma Therapeutics, Inc. |
Methods of responding to a biothreat
|
|
CN104114572A
(zh)
*
|
2011-12-16 |
2014-10-22 |
现代治疗公司 |
经修饰的核苷、核苷酸和核酸组合物
|
|
WO2013113325A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Negatively charged nucleic acid comprising complexes for immunostimulation
|
|
AU2013243948A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins associated with human disease
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
|
WO2013174409A1
(en)
|
2012-05-25 |
2013-11-28 |
Curevac Gmbh |
Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
|
|
US10245229B2
(en)
*
|
2012-06-08 |
2019-04-02 |
Translate Bio, Inc. |
Pulmonary delivery of mRNA to non-lung target cells
|
|
US9512456B2
(en)
|
2012-08-14 |
2016-12-06 |
Modernatx, Inc. |
Enzymes and polymerases for the synthesis of RNA
|
|
WO2014093924A1
(en)
|
2012-12-13 |
2014-06-19 |
Moderna Therapeutics, Inc. |
Modified nucleic acid molecules and uses thereof
|
|
AU2013343864B2
(en)
|
2012-11-09 |
2019-04-04 |
BioNTech SE |
Method for cellular RNA expression
|
|
WO2014071963A1
(en)
|
2012-11-09 |
2014-05-15 |
Biontech Ag |
Method for cellular rna expression
|
|
WO2014081507A1
(en)
|
2012-11-26 |
2014-05-30 |
Moderna Therapeutics, Inc. |
Terminally modified rna
|
|
WO2014093574A1
(en)
|
2012-12-13 |
2014-06-19 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for altering cell phenotype
|
|
CA2901501C
(en)
*
|
2013-02-21 |
2023-03-07 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Vaccine composition
|
|
RU2718988C2
(ru)
|
2013-02-22 |
2020-04-15 |
Куревак Аг |
Комбинация противораковой рнк-вакцины и ингибитора пути pd-1 и ее применение
|
|
WO2014160243A1
(en)
|
2013-03-14 |
2014-10-02 |
The Trustees Of The University Of Pennsylvania |
Purification and purity assessment of rna molecules synthesized with modified nucleosides
|
|
EP2971010B1
(en)
|
2013-03-14 |
2020-06-10 |
ModernaTX, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
DK2970456T3
(da)
*
|
2013-03-14 |
2021-07-05 |
Translate Bio Inc |
Fremgangsmåder og sammensætninger til levering af mrna-kodede antistoffer
|
|
WO2014144767A1
(en)
|
2013-03-15 |
2014-09-18 |
Moderna Therapeutics, Inc. |
Ion exchange purification of mrna
|
|
US20160032273A1
(en)
|
2013-03-15 |
2016-02-04 |
Moderna Therapeutics, Inc. |
Characterization of mrna molecules
|
|
US10130649B2
(en)
*
|
2013-03-15 |
2018-11-20 |
Translate Bio, Inc. |
Synergistic enhancement of the delivery of nucleic acids via blended formulations
|
|
WO2015013551A1
(en)
|
2013-07-25 |
2015-01-29 |
Marshall Christopher Patrick |
Conformationally stabilized rsv pre-fusion f proteins
|
|
BR112016003361A2
(pt)
|
2013-08-21 |
2017-11-21 |
Curevac Ag |
vacina do vírus sincicial respiratório (rsv)
|
|
SG11201510747RA
(en)
|
2013-08-21 |
2016-03-30 |
Curevac Ag |
Method for increasing expression of rna-encoded proteins
|
|
US10821175B2
(en)
*
|
2014-02-25 |
2020-11-03 |
Merck Sharp & Dohme Corp. |
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
|
|
SG10201912038TA
(en)
|
2014-04-23 |
2020-02-27 |
Modernatx Inc |
Nucleic acid vaccines
|
|
CN106659777A
(zh)
|
2014-06-13 |
2017-05-10 |
葛兰素史密丝克莱恩生物有限公司 |
免疫原性组合产品
|
|
JP2017523777A
(ja)
|
2014-07-17 |
2017-08-24 |
モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． |
ポリヌクレオチドの末端修飾
|
|
WO2016164762A1
(en)
|
2015-04-08 |
2016-10-13 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
|
|
RU2749113C2
(ru)
|
2015-04-22 |
2021-06-04 |
Куревак Аг |
Содержащая рнк композиция для лечения опухолевых заболеваний
|
|
US20180303925A1
(en)
|
2015-04-27 |
2018-10-25 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-Modified RNA For Inducing an Adaptive Immune Response
|
|
EP3307305A4
(en)
|
2015-06-10 |
2019-05-22 |
Modernatx, Inc. |
TARGETED ADAPTIVE VACCINES
|
|
EP3307308A2
(en)
*
|
2015-06-10 |
2018-04-18 |
Hookipa Biotech AG |
Hpv vaccines
|
|
US20180296663A1
(en)
|
2015-06-17 |
2018-10-18 |
Curevac Ag |
Vaccine composition
|
|
EP3324979B1
(en)
|
2015-07-21 |
2022-10-12 |
ModernaTX, Inc. |
Infectious disease vaccines
|
|
WO2017015457A1
(en)
|
2015-07-21 |
2017-01-26 |
Modernatx, Inc. |
Ebola vaccine
|
|
WO2017019935A1
(en)
|
2015-07-30 |
2017-02-02 |
Modernatx, Inc. |
Multimeric mrna
|
|
WO2017020026A1
(en)
|
2015-07-30 |
2017-02-02 |
Modernatx, Inc. |
Concatemeric peptide epitopes rnas
|
|
WO2017031241A1
(en)
|
2015-08-17 |
2017-02-23 |
Modernatx, Inc. |
Rna mapping/fingerprinting
|
|
WO2017031232A1
(en)
|
2015-08-17 |
2017-02-23 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
|
EP4286012A3
(en)
|
2015-09-17 |
2024-05-29 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
AU2016336344A1
(en)
|
2015-10-05 |
2018-04-19 |
Modernatx, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
|
WO2017066789A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified sugar
|
|
MX2018004917A
(es)
|
2015-10-22 |
2019-04-01 |
Modernatx Inc |
Vacuna de virus sincitial respiratorio.
|
|
WO2017070620A2
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
EP3364981A4
(en)
|
2015-10-22 |
2019-08-07 |
ModernaTX, Inc. |
VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
|
|
CA3002912A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Nucleic acid vaccines for varicella zoster virus (vzv)
|
|
EP3364950A4
(en)
|
2015-10-22 |
2019-10-23 |
ModernaTX, Inc. |
VACCINES AGAINST TROPICAL DISEASES
|
|
EP3364949A4
(en)
|
2015-10-22 |
2019-07-31 |
ModernaTX, Inc. |
CANCER VACCINES
|
|
US20180289792A1
(en)
|
2015-10-22 |
2018-10-11 |
ModernaTX. Inc. |
Sexually transmitted disease vaccines
|
|
AU2016342049B2
(en)
|
2015-10-22 |
2023-05-18 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
TW201729835A
(zh)
|
2015-10-22 |
2017-09-01 |
現代公司 |
呼吸道病毒疫苗
|
|
HRP20220652T1
(hr)
|
2015-12-10 |
2022-06-24 |
Modernatx, Inc. |
Pripravci i postupci unosa terapijskih sredstava
|
|
WO2017201347A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
|
|
EP3458106A4
(en)
|
2016-05-18 |
2020-03-18 |
Modernatx, Inc. |
POLYNUCLEOTIDS FOR CODING LIPOPROTEIN LIPASE FOR TREATING HYPERLIPIDEMIA
|
|
KR20230074598A
(ko)
|
2016-05-18 |
2023-05-30 |
모더나티엑스, 인크. |
릴랙신을 인코딩하는 폴리뉴클레오타이드
|
|
MA45052A
(fr)
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
|
|
CN116837052A
(zh)
|
2016-09-14 |
2023-10-03 |
摩登纳特斯有限公司 |
高纯度rna组合物及其制备方法
|
|
MA46584A
(fr)
|
2016-10-21 |
2019-08-28 |
Modernatx Inc |
Vaccin contre le cytomégalovirus humain
|
|
EP3532613A4
(en)
|
2016-10-26 |
2020-05-06 |
ModernaTX, Inc. |
METHOD AND COMPOSITIONS FOR RNA MAPPING
|
|
SG11201903674YA
(en)
|
2016-10-26 |
2019-05-30 |
Modernatx Inc |
Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
|
|
BR112019008481A2
(pt)
|
2016-10-26 |
2020-03-03 |
Curevac Ag |
Vacinas de mrna de nanopartículas lipídicas
|
|
WO2018089851A2
(en)
|
2016-11-11 |
2018-05-17 |
Modernatx, Inc. |
Influenza vaccine
|
|
WO2018107088A2
(en)
|
2016-12-08 |
2018-06-14 |
Modernatx, Inc. |
Respiratory virus nucleic acid vaccines
|
|
WO2018111967A1
(en)
|
2016-12-13 |
2018-06-21 |
Modernatx, Inc. |
Rna affinity purification
|
|
US20180243225A1
(en)
|
2017-01-25 |
2018-08-30 |
Modernatx, Inc. |
Ebola/marburg vaccines
|
|
EP3576751A4
(en)
|
2017-02-01 |
2021-08-04 |
ModernaTX, Inc. |
RNA ANTI-CANCER VACCINES
|
|
WO2018144778A1
(en)
|
2017-02-01 |
2018-08-09 |
Modernatx, Inc. |
Polynucleotide secondary structure
|
|
WO2018151816A1
(en)
|
2017-02-16 |
2018-08-23 |
Modernatx, Inc. |
High potency immunogenic compositions
|
|
WO2018170245A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
US11752206B2
(en)
|
2017-03-15 |
2023-09-12 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
US11045540B2
(en)
|
2017-03-15 |
2021-06-29 |
Modernatx, Inc. |
Varicella zoster virus (VZV) vaccine
|
|
EP3595713A4
(en)
|
2017-03-15 |
2021-01-13 |
ModernaTX, Inc. |
RESPIRATORY SYNCYTIAL VIRUS Vaccine
|
|
MA47790A
(fr)
|
2017-03-17 |
2021-05-05 |
Modernatx Inc |
Vaccins à base d'arn contre des maladies zoonotiques
|
|
WO2018175783A1
(en)
|
2017-03-22 |
2018-09-27 |
Modernatx, Inc. |
Rna bacterial vaccines
|
|
WO2018187590A1
(en)
|
2017-04-05 |
2018-10-11 |
Modernatx, Inc. |
Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
|
|
MA49463A
(fr)
|
2017-04-26 |
2021-05-05 |
Modernatx Inc |
Vaccin contre le virus de l'herpès simplex
|
|
US11786607B2
(en)
|
2017-06-15 |
2023-10-17 |
Modernatx, Inc. |
RNA formulations
|
|
WO2018232355A1
(en)
|
2017-06-15 |
2018-12-20 |
Modernatx, Inc. |
Rna antibodies
|